Table 1 General characteristics of studies. Values are numbers (percentages) unless stated otherwise
Characteristics | Live birth (n = 25) | Ongoing pregnancy (n = 43) |
|---|---|---|
Study characteristics | ||
 Median (range) study sample size | 355 (38–1983) | 237 (38–1983) |
Continent | ||
 North America | 5 (20) | 9 (21) |
 Europe | 9 (36) | 17 (40) |
 Asia | 7 (28) | 11 (26) |
 World wide | 2 (8) | 2 (5) |
 Other | 2 (8) | 4 (9) |
Type of interventions/controls | ||
 Placebo/no LPS treatment | 2 (8) | 6 (14) |
 HCG | 2 (8) | 5 (12) |
 Progesterone | 24 (96) | 39 (91) |
 Combineda | 6 (24) | 11 (26) |
Patient characteristics | ||
 Median (range) age (years); No in group | 32.4 (28.4–35.5); n = 24 | 32.1 (28.4–35.4); n = 40 |
Ovarian stimulation | ||
 Long GnRH agonist protocol | 14 (56) | 24 (56) |
 GnRH antagonist protocol | 1 (4) | 5 (12) |
 Other protocol | 4 (16) | 6 (14) |
 Combined | 6 (24) | 8 (19) |
Fertilization | ||
 IVF | 13 (52) | 23 (53) |
 ICSI | 2 (8) | 7 (16) |
 IVF/ICSI | 10 (40) | 13 (30) |
Timing LPS after oocyte retrieval | ||
 Within 48 h | 18 (72) | 31 (72) |
 48–96 h | 4 (16) | 12 (28) |
 Not stated | 5 (20) | 5 (12) |